Full Press Release Details
UPPSALA, 17 June, 2013
Novavax to make initial Form S-4 registration statement filing
Isconova AB (publ) ("Isconova") announces that Novavax
Inc. ("Novavax") expects to make its initial filing today of a Registration Statement on Form S-4 with the U.S. Securities
and Exchange Commission (SEC) under the name Novavax, Inc.
The registration statement, which is expected to be publicly
available on SEC's website around 6 a.m. EST., provides the details of the previously announced offer for the shares and
warrants in Isconova. The registration statement has not yet become effective.
Isconova notes that Novavax has communicated its expectation
that the offer document to holders of shares and warrants in Isconova will be distributed as soon as possible after the Registration
Statement is declared effective.
Uppsala 17 June, 2013
The Board of Directors
For further information, please contact:
Sven Andr asson, CEO Isconova
Tel: +46-701-60 60 60
E-mail: sven.andreasson@isconova.com
Isconova AB is a leading international vaccine adjuvant company. Isconova has deep knowledge of vaccine systems, and the company
develops vaccines together with partners in the human and veterinary markets. The first vaccine using Isconova's nano-particle
Matrix technology, Equilis Prequenza, was launched on the veterinary market in 2006. In the human market a number of vaccines
are under development with Isconova's third generation nano-particle, Matrix-M . Isconova's partners include
Crucell/J&J, Pfizer, Merck & Co., The Jenner Institute, Virbac and Genocea. The Company is headquartered in Uppsala, Sweden.
Isconova AB is listed on NASDAQ OMX First North Premier (ticker: ISCO). Pareto hman AB is the Company's Certified
Adviser. Additional information about Isconova is available on the company's website, www.isconova.com.
Additional Information
This communication does not constitute an offer to sell or the solicitation of an offer to buy any securities or a solicitation
of any vote or approval. In connection with the proposed combination of Novavax and Isconova, Novavax intends to file with the
Securities and Exchange Commission ("SEC") a Registration Statement on Form S-4 that will include a preliminary prospectus
of Novavax. These materials are not final and may be amended. Novavax urges investors to read the S-4 prospectus and the Swedish
offer document regarding the proposed combination when they become available, as well as other documents filed with the SEC and
with the Swedish Financial Supervisory Authority, because they will contain important information. You may obtain copies of all
documents filed with the SEC regarding this proposed transaction, free of charge, at the SEC's website (www.sec.gov). You
may also obtain the documents filed with the SEC, free of charge, from Novavax's website (www.novavax.com) under the tab
"Investor Info" and then under the heading "SEC Filings."